27-28 June 2018
Singapore

Twitter logo for website footers 2

 

Speakers

Expand/Collapse

Zhang Yu
President & CEO
Aeon Therapeutics

Day One

Wednesday 27th June, 2018

14.00 | Developing TCR-mimic CAR-T to Treat Patients with Solid Tumors in China

Zonghai Li
CEO
CARsgen Therapeutics

Day One

Wednesday 27th June, 2018

12.30 | Development of CAR-T Against Solid Tumors

Day Two

Thursday 28th June, 2018

13.00 | Panel: Can we Make Allogeneic CAR-T Therapies a Reality?

Jennifer Chow
Global Commercial CAR-T Lead
Celgene

Day Two

Thursday 28th June, 2018

13.00 | Panel: Can we Make Allogeneic CAR-T Therapies a Reality?

16.00 | Panel Discussion: How do we ensure ease of accessibility and affordability to patients?

Tony Liu
CEO
Cellular Biomedicine Group

Day Two

Thursday 28th June, 2018

15.00 | Cell Characterization to Understand Cell Mechanisms and Behaviour

Mark Sawicki
CCO
Cryoport

Day Two

Thursday 28th June, 2018

15.30 | Cryo Chain Strategies: From Research to Commercialization

Crystal Sun
CEO Assistant & Director, Regulatory & Government Affairs
Fosun Kite Biotech

Day One

Wednesday 27th June, 2018

10.30 | Question Time: Leader Q&A

10.00 | Commercialization Experience from Yescarta’s Debut

Philip Vanek
GM, Cell Therapy Growth Strategy
GE Healthcare

Day Two

Thursday 28th June, 2018

12.30 | Smart, Closed & Connected Solutions for Cell Therapy Production

Patrick Hanley
Laboratory Facility Director, Cellular Therapy Stem & Cell Processing, Assistant Professor of Pediatrics, Children's National Health System
The George Washington University

Day One

Wednesday 27th June, 2018

15.30 | Overcoming Challenges in the Cellular Therapy Laboratory

Ting He
CEO
ImmunoChina Pharmaceuticals

Day Two

Thursday 28th June, 2018

10.00 | Development of CAR-T Therapy for Hematological Malignancies

Lei Xiao
CEO
Innovative Cellular Therapeutics

Sicco Popma
CEO
IO Biosciences

Day Two

Thursday 28th June, 2018

16.00 | Panel Discussion: How do we ensure ease of accessibility and affordability to patients?

Ian Johnston
Industrial & Academic Cooperations Manager, Senior Project Manager
Miltenyi Biotec

Day Two

Thursday 28th June, 2018

12.00 | Simplifying CAR T Cell Manufacture Through the Use of a Single, Closed System Device

Frank Fan
CSO, Interim CEO
Nanjing Legend Biotechnology

Day Two

Thursday 28th June, 2018

09.30 | Clinical Update on Anti-BCMA CAR-T: LCAR-B38M

Pascal Touchon
Senior Vice President, Global Head Cell & Gene
Novartis Oncology

Day One

Wednesday 27th June, 2018

10.30 | Question Time: Leader Q&A

09.30 | Kymriah: The Journey of the First Approved CAR-T from Bench to Ensuring Global Availability for Patients

Jim Freeth
Co-managing Director
Retrogenix

Day One

Wednesday 27th June, 2018

14.30 | Screening CAR T Cells for Target Specificity Using Human Cell Microarray Technology

Henry Ji
CEO
Sorrento Therapeutics

Day One

Wednesday 27th June, 2018

12.00 | Quo Vadis CAR-T! The Next Frontiers in Cell Therapies

John Connolly
CSO
Tessa Therapeutics

Peter Sun
CEO
TIMMUNE

Day Two

Thursday 28th June, 2018

10.30 | Phase 1 Clinical Study of TriCAR-T/CD19 for the Treatment of Non-Hodgkin Lymphoma